3，4苯并芘对内皮祖细胞生物学功能的影响

目的研究3,4苯并芘（BaP）对人脐血来源的内皮祖细胞（EPC）生物学功能的影响。方法密度梯度离心法分离获取人脐血单个核细胞,采用贴壁培养法培养MNC中的EPC,通过Dil标记的乙酰化低密度脂蛋白（Dil-ac-LDL）摄取实验和FITC标记的植物凝集素（FITC-UEA-I lectin）结合实验鉴定细胞。消化收集第3代细胞,分别采用细胞计数试剂盒（CCK-8）、黏附能力测定实验、Transwell小室法及Matrigel体外成血管试验观察BaP对EPC增殖能力、粘附能力、迁移能力及成血管能力的影响,并检测各组细胞培养上清液SOD含量。采用单因素方差分析及LSD-t检验进行统计学分析。结果采用贴壁培养法能成功培养出EPC;与正常对照组相比,BaP呈浓度依赖性降低EPC的增殖能力{正常对照组OD（1.02±0.04）显著高于BaP各组[BaP①组OD（0.66±0.04）,BaP②组OD（0.55±0.04）,BaP③组OD（0.35±0.05）,均P〈0.01],BaP染毒组间增殖能力差异亦有统计学意义（两两比较,均P〈0.01）};与正常对照组比较,BaP呈浓度依赖性降低EPC的黏附能力{正常对照组[（117.50±17.16）个/200倍镜]显著高于BaP各组[BaP①组（80.00±14.46）个/200倍镜,BaP②组（66.00±9.06）个/200倍镜,BaP③组（49.80±10.72）个/200倍镜,均P〈0.01],BaP染毒组间黏附能力差异亦有统计学意义（两两比较,均P〈0.05）};与正常对照组相比,EPC的迁移能力亦呈BaP浓度依赖性降低{正常对照组[（46.10±4.51）个/400倍镜]显著高于BaP各组[BaP①组（35.50±4.95）个/400倍镜,BaP②组（26.80±4.08）个/400倍镜,BaP③组（19.50±2.84）个/400倍镜,均P〈0.01],BaP染毒组间迁移能力差异亦有统计学意义（两两比较,均P〈0.01）};与正常对照组比较,EPC的成血管能力亦呈BaP浓度依赖性降低{正常对照组[（33.20±3.70）个/100倍镜]显著高于BaP各组[BaP①组（22.00±3.39）个/100倍镜,BaP②组（16.20±2.59）个/100倍镜,BaP③组（10.80±2.39）个/100倍镜,均P〈0.01],BaP染毒组间成血管能力差异亦有统计学意义（两两比较,均P〈0.05）}。同时细胞培养上清液中SOD的活力也呈BaP浓度依赖性地降低{正常对照组[（22.6±2.19）U/ml]高于BaP各组[BaP①组（15.94±1.68）U/ml,BaP②组（12.5±1.58）U/ml,BaP③组（6.9±1.55）U/ml,均P〈0.01],BaP染毒组间SOD活力差异亦有统计学意义（两两比较,均P〈0.01）}。结论 BaP体外诱导显著影响EPC的多种生物学功能,其机制可能与氧化损伤有关。     

不同方法建立多重耐药铜绿假单胞菌肠道感染动物模型的比较和评价

目的探讨建立肠道多重耐药细菌感染动物模型的方法,为实验研究和治疗因耐药菌引起的感染提供良好的模型。方法 24只6周龄SPF级雄性BALB/c小鼠分成4组:正常对照组、MDR-PA组、MDR-PA+抗生素组和MDR-PA+禁食组,6只/组。分别给予生理盐水灌胃、PA悬液灌胃、自由饮用含头孢曲松钠水后PA悬液灌胃和禁食后PA悬液灌胃。实验结束后对结肠组织进行病理学观察和炎症评分;检测炎症因子TNF-α和INF-γ浓度。结果结肠组织病理表现出不同程度的炎症变化;炎症因子TNF-α和INF-γ浓度较对照组均明显增加,有显著统计学意义。结论三种方法均可成功建立肠道多重耐药铜绿假单孢菌感染的动物模型,可根据不同实验目的选择不同的建立模型方法。     

重组腺相关病毒(rAAV)介导的人凝血因子Ⅸ高活性突变衍生物在血友病B基因治疗研究中的应用

采用定点诱变技术, 将R338A点突变引入人凝血因子Ⅸ基因, 并构建于AAV载体上, 以rHSV/AAV杂合辅助病毒系统介导制备rAAV-hFIX重组病毒, 然后, 经肌肉注射对血友病B小鼠进行治疗实验, 观察该突变基因在小鼠体内的表达、活性以及机体对该突变衍生物的免疫反应与治疗效果. 结果显示: (i)治疗小鼠体内可检测到hFIX-R338A突变衍生物的存在, 并持续15周以上; (ii)突变衍生物hFIX-R338A在小鼠血浆中的凝血活性达(34.2±5.23)%, 显著高于野生型Ⅸ因子凝血活性((14.27±3.4)%); (iii)治疗小鼠体内未检测到抗Ⅸ因子突变衍生物抗体的存在; (iv)未发现与治疗相关的局部及全身性毒副作用. 提示: 以AAV介导人凝血因子Ⅸ高活性突变衍生物hFIX-R338A基因治疗可能成为替代野生型Ⅸ因子进行血友病B基因治疗的一个更为有效的途径.     

重组腺相关病毒(rAAV)介导的人凝血因子IX高活性突变衍生物在血友病B基因治疗研究中的应用

采用定点诱变技术,将R338A点突变引入人凝血因子Ⅸ基因,并构建于AAV载体上,以rHSV/AAV杂合辅助病毒系统介导制备rAAV-hFIX重组病毒,然后,经肌肉注射对血友病B小鼠进行治疗实验,观察该突变基因在小鼠体内的表达、活性以及机体对该突变衍生物的免疫反应与治疗效果.结果显示:(i)治疗小鼠体内可检测到hFIX-R338A突变衍生物的存在,并持续15周以上;(ii)突变衍生物hFIX-R338A在小鼠血浆中的凝血活性达(34.2±5.23)%,显著高于野生型Ⅸ因子凝血活性((14.27±3.4)%);(iii)治疗小鼠体内未检测到抗Ⅸ因子突变衍生物抗体的存在;(iv)未发现与治疗相关的局部及全身性毒副作用.提示:以AAV介导人凝血因子Ⅸ高活性突变衍生物hFLX-R338A基因治疗可能成为替代野生型Ⅸ因子进行血友病B基因治疗的一个更为有效的途径.     

农用抗菌素5102的研究I. 产生菌的分类鉴定

从我国湖北省应城县水稻田土壤中分离到一株链霉菌,编号为5102。根据其形态、培养特征、生理特性和抗菌谱等的研究结果,该菌株属于吸水链霉菌类群,但不同于已报道的相近似菌种,为吸水链霉菌的一个新变种,定名为吸水链霉菌应城变种(Streptomyces hygroscopicusvar．Yingchengensis Yan et Ruan n. var.)     

稻田蛛间消长及保护利用

一、稻田蜘蛛的田间消长 1976年我们在本院农场及汉阳县汉乐大队调查了未施过农药的早、中、晚稻田内的蜘蛛     

Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX

A mutant human factor IX with arginine at 338 residual changed to alanine (hFIXR338A) by site-directed mutagenesis was introduced into AAV vectors, and a recombinant adeno-associ-ated viral vector containing hFIXR338A, prepared by rHSV/AAV hybrid helper virus system, was directly introduced to the hind leg muscle of factor IX knock out mice. The expression and the biological activity of human factor IX mutant, hFIXR338A, and the immune response against it in the treated mice were assayed and detected. The results showed that (i) the high-level expression of human factor IX mutant protein, hFIXR338A, has been detected in rAAV-hFIXR338A treated hemophilia B mice and lasted more than 15 weeks; (ii) the clotting activity of hFIXR338A in plasma is 34.2%± 5.23%, which is remarkably higher than that of (14.27%±3.4%) of wild type hFIX treated mice in the activated partial thromboplastin assay; (iii) immune response against factor IX R338A was absent, with no factor IX mutant protein (hFIXR338A) inhibitors deve     

Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX

A mutant human factor IX with arginine at 338 residual changed to alanine (hFIXR338A) by site-directed mutagenesis was introduced into AAV vectors, and a recombinant adeno-associ- ated viral vector containing hFIXR338A, prepared by rHSV/AAV hybrid helper virus system, was directly introduced to the hind leg muscle of factor IX knock out mice. The expression and the biological activity of human factor IX mutant, hFIXR338A, and the immune response against it in the treated mice were assayed and detected. The results showed that (i) the high-level expression of human factor IX mutant protein, hFIXR338A, has been detected in rAAV-hFIXR338A treated hemophilia B mice and lasted more than 15 weeks; (ii) the clotting activity of hFIXR338A in plasma is 34.2%± 5.23%, which is remarkably higher than that of (14.27% ± 3.4%) of wild type hFIX treated mice in the activated partial thromboplastin assay; (iii) immune response against factor IX R338A was absent, with no factor IX mutant protein (hFIXR338A) inhibitors development in the treated mice; and (iv) no local or systemic side-effects and toxicity associated with the gene transfer were found. It demonstrated the potential use of treating hemophilia B by recombinant adeno-associated viral vectors with mutant hFIXR338A gene, an alternative strategy for hemophilia B gene therapy to wild-type human factor IX.     

Muscle injection of rAAV/mFIX to secrete clotting factor IX corrects the hemorrhagic tendencies in hemophilia B mice

Recombinant AAV particles of high titer (>1013 virus genome/mL) were prepared according to the rHSV/AAV helper virus method. After intramuscular injection of viral vectors in the hind limb, a sustained elevated level (>370 ng/mL) of murine FIX expression in the plasma of hemophilia B mouse was detected and persisted for more than 350 days. The biological activity reached 30% of normal levels, and bleeding symptoms in the treated mice were significantly alleviated. No anti-FIX antibody (inhibitor) was detected, though anti-AAV antibodies were found at a very low level after single injection. Repeated injection with rAAV/mFIX led to a variation in anti-AAV antibody levels between the two groups which had received different doses. Results from tissue analysis confirmed the skeletal muscle as the origin for circulating functional mFIX. Our results suggest that AAV-mediated gene transfer offers a promising method of gene therapy for hemophilia B.     

绞股蓝细胞培养及其某些生理生化特性

从绞股蓝幼叶诱导并筛选出了胚性愈伤组织,其悬浮培养细胞生长曲线呈S形,生长周期中培养液pH值先降低后回升,可溶性糖含量避渐降低,培养细胞可溶性蛋白质含量及过氧化物酶活性出现两个高峰,过氧化物酶谱带数目无变化。培养细胞能合成皂苷,静止期皂苷含量最高。